Based on a high level of expertise and exclusive technologies, BIOTEM implements the most relevant strategies for each project and is pledged to achieve the results outlined in the contract.

Our services include the development of monoclonal antibodies from the hybridoma generation stages up to in vitro or in vivo antibody production at any scale, antisera production, antibody purification and modification, immunoassay development and customised studies.

Besides, BIOTEM is strongly involved in different R&D programmes developed either internally or in collaboration. These programmes aim to:

• Optimise and develop new approaches for human and murine antibodies
• Develop monoclonal antibodies against relevant targets for diagnostic and therapeutic purposes